Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is
administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD
patients over the age of 8 years.